Drugmaker Medigen Biotechnology Corp (基亞生技) yesterday said its Japanese partner Oncolys Biopharma Inc has reached licensing and capital tie-up agreements with a third party regarding the OBP-301 liver cancer medicine, which is expected to benefit the Taiwanese firm based on the terms of their partnership.
Medigen said in a regulatory filing that based on its strategic alliance and licensing agreement with Oncolys, the company could enjoy up to one-third of commercial interests of OBP-301 (Telomelysin).
As the licensing agreement is to take effect on April 24, Medigen would see a licensing contribution from the deal later this month and other milestone payments after that.
OBP-301 is a cancer treatment developed by Medigen and Oncolys over more than 10 years.
It is currently being tested in clinical trials for people with esophageal cancer in Japan, for treatment of gastric cancer in the US, as well as in Taiwan and South Korea for liver cancer patients, Medigen said.
Earlier yesterday, Oncolys entered into an agreement with Chugai Pharmaceutical Co Ltd, granting the latter an exclusive license, with sublicensing rights for the development, manufacture and marketing of OBP-301 in Taiwan and Japan, Medigen said.
Oncolys and Chugai, a member of the Roche Group, also reached a licensing agreement that grants Chugai an exclusive option on the worldwide development, manufacture and marketing of OBP-301, excluding Taiwan, Japan, China, Hong Kong and Macau, the filing said.
According to a statement Oncolys posted on its Web site, the company is to receive ¥550 million (US$4.93 million) from Chugai as an upfront payment for the exclusive licensing agreement.
If a certain level of efficacy is confirmed in the clinical studies of OBP-301, and should Chugai exercise the exclusive option, the total value of the licensing deal would be ¥50 billion or more, Oncolys said.
After the commercial launch of OBP-301, Oncolys could also receive royalties on Chugai’s sales of the drug, it added.
Oncolys is to issue ¥800 million of new common shares to Chugai.
Medigen posted cumulative revenue of NT$72.41 million (US$2.35 million) in the first two months of this year.
The company remained in the red last year, with a net loss of NT$442.67 million, compared with a net loss of NT$466.75 million the previous year.
Sales during the period declined 4.72 percent to NT$407.31 million.
Losses per share were NT$3.05 last year.
Medigen shares yesterday rose 0.33 percent to close at NT$61.2 in Taipei trading.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained